胃肠间质瘤的治疗进展

Progress in the treatment of gastrointestinal stromal tumor

作为胃肠道最常见的一类间叶源性肿瘤,胃肠间质瘤(GIST)越来越受到关注。近10年来,随着对GIST分子机制研究的深入,以伊马替尼为代表的分子靶向药物的出现,改变了GIST的传统治疗理念,形成了外科手术联合分子靶向药物的治疗模式。靶向药物在GIST的术前、术后辅助治疗及晚期GIST中的应用显著改善了患者的预后,延长了生存时间。但是,针对不同期别的GIST,应该如何合理应用这些靶向药物,临床还有很多问题亟待解决。本文就GIST的围手术期治疗及晚期GIST治疗的最新进展作一综述。

As the most common mesenchymal tumor of gastrointestinal tract,gastrointestinal stromal tumor（ GIST） has been paid more and more attention. In the recent 10 years,with studies on molecular mechanism of GIST,and emergence of molecular targe-ted drugs represented by imatinib mesylate,traditional treatment concepts of GIST have been updated. Surgical resection combined with molecular targeted drugs is becoming the treatment mode for GIST. Molecular targeted therapy has significantly improved the prognosis and prolong the survival of GIST patients. However, for different stages of GIST,many questions on how to apply the targeted drugs rea-sonably still remain to be answered. This article summarizes the latest progress on the perioperative treatment of GIST and systemic ther-apy for advanced GIST.